On June 11, Liquidia rose 7.26% in regular trading, trading at $69.98/share, with turnover of $54.99 million.

On the news front, Liquidia announced it will present research posters at the PHA International Pulmonary Hypertension Conference and Scientific Sessions, highlighting continued R&D progress in its core pulmonary arterial hypertension (PAH) treatment area. The company focuses on developing inhaled therapies through its proprietary PRINT particle engineering technology platform, with lead product YUTREPIA targeting PAH and PH-ILD indications. The catalyst builds on strong recent momentum, with the stock having surged over 15% in the prior week amid growing market attention to its PAH pipeline.

Within the Pharmacy sector, the overall performance was positive. Among individual stocks, Pfizer up 2.91%, Eli Lilly up 2.26%, Merck up 1.5%, Johnson & Johnson up 0.95%, Zoetis down 0.76%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)